anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Reflective Supervision enhancement is a professional development series for supervisors of state pre-kindergarten programs that is designed to build skills in using Reflective Supervision with teachers. The goal of the Reflective Supervision enhancement is to provide supervisors with foundational knowledge in Reflective Practice and Supervision and increase their use of Reflective Supervision principles and practices within their work. The series consists of a day-long foundational training and nine skills-focused workshops. Supervisors are expected to receive 8 hours of foundational training prior to the start of the academic year, and nine 2-hour monthly small groups over the course of the academic year.
Trastuzumab is widely used in HER2 breast cancer. However, it may cause left ventricular (LV) dysfunction. A decrease in LV global longitudinal strain (GLS) has been previously demonstrated to be a good predictor of subsequent cancer therapy related dysfunction (CTRCD). Left atrial morphological remodeling during Trastuzumab therapy has also been shown. The aim of this study is exploring the relationship between early changes in left atrial function and the development of Trastuzumab-induced cardiotoxicity. Consecutive patients with diagnosis of HER2+non-metastatic breast cancer treated with Trastuzumab were prospectively enrolled. A clinical, conventional, and advanced echocardiographic assessment was performed at baseline and every three months, until a one-year follow-up was reached. One-hundred-sixteen patients completed the 12 months follow-up, 10 (9%) cases of CTRCD were observed, all after the sixth month. GLS and LVEF significantly decreased in the CTRCD group at 6 months of follow-up, with an earlier (3 months) significant worsening in left atrial morpho-functional parameters. Systolic blood pressure, early peak atrial longitudinal strain (PALS), peak atrial contraction (PACS) and left atrial volume (LAVI) changes resulted independent predictors of CTRCD at multivariable logistic regression analysis. Moreover, early changes in PALS and PACS resulted good predictors of CTRCD development (AUC 0.85; p = 0.008, p < 0.001 and 0.77; p = 0.008, respectively). This prospective study emphasizes that the decline in PALS and PACS among trastuzumab-treated patients could possibly increase the accuracy in identifying future CTRCD in non-metastatic HER2 breast cancer cases, adding predictive value to conventional echocardiographic assessment.
Acute myocardial infarction (AMI) is caused by acute occlusion of the coronary artery and interruption of blood flow, which leads to myocardium necrosis in the blood supply area of the culprit vessel. AMI can lead to the loss of cardiomyocytes, which in turn causes ventricular enlargement, myocardial hypertrophy, eventually leading to the decline of cardiac function. In severe cases，AMI may even result in acute or chronic heart failure (HF). Patients with HF after MI have significantly decreased quality of life, high mortality and poor clinical prognosis. Studies have shown that the incidence of HF in patients with ST-segment elevation myocardial infarction (STEMI) is about 21.8%, and the 30-day mortality rate of patients with HF after MI is up to 25%. The occurrence of HF after MI is associated with various factors. Advanced age, hypertension, diabetes, renal insufficiency, rapid heart rate, atrial fibrillation (AF), low left ventricular ejection fraction (LVEF), stroke are all risk factors. Actively controlling these factors is crucial. However, due to the lack of medical knowledge, poor self-mobility among HF patients, outpatient management faces severe challenges. Therefore, strengthening outpatient management for patients with HF after MI is of great significance in alleviating clinical symptoms and improving patients' exercise capacity.

Recently, the digital health intervention (DHI) industry composed of internet, artificial intelligence (AI), mobile terminals and wearable devices has developed rapidly worldwide, which plays an important role in health care. DHI has shown promising prospects in the management of cardiovascular diseases. It can be used for AF screening, blood pressure management, and reducing mortality in HF patients, among other applications. However, the use in patients with HF after MI lacks large-scale evidence-based medical support.

Therefore, this study has independently designed the HeartMed-HF digital heart failure clinical management system for patients with HF after MI. The system monitors patients' weight, heart rate, blood pressure, fluid intake and output, and other HF evaluation indicators at home using wearable devices. Combining data from patients' medical histories, laboratory test results, and surgical records, the system uses AI algorithms to generate personalized outpatient HF management plans, achieving precise home-based clinical management for patients. The core management components include health education, symptom management, continuous monitoring, risk warning, medication management, and cardiac exercise rehabilitation. Additionally, the study will form a comprehensive clinical management team consisting of physician assistants, rehabilitation trainers, nutritionists, psychologists, and health managers. Through an internet platform and mobile terminals, the system closely connects patients and doctors, extending inpatient treatment to the home and realizing a closed-loop clinical management model that integrates real-time monitoring, early warning, and timely intervention.
This is a prospective, single center, randomized, intra-individual study with blinded evaluators assessing the efficacy and safety of STYLAGE® HydroMax on skin moisturization and elasticity on the cheek and neckline area. Forty seven female subjects will be enrolled and will receive 3 injections of product one month apart on the cheek and neckline area in a randomized fashion with the contralateral non-treated cheek and neckline area. Injection will be performed into the mid to deep dermis of the cheek and neckline area (1 mL per session and per area) by micro-papular injection technique. Subjects will be followed up at 1, 2, 3, 4, 6 and 9 months timepoints. Variation of moisturization, elasticity and roughness of treated areas in comparison with non-treated areas will be measured using Corneometer®, Cutometer®, Dermatop® or Primos Lite® respectively. Global aesthetic improvement, subject satisfaction, pain at injection and safety will also be assessed.
BACKGROUND: Mortality in patients with acute onset of impaired consciousness is high: as many as 10% do not survive. The spectrum of differential diagnoses is wide, and more than one underlying condition is found in one-third of all cases. In this article, we describe a structured approach to patients with acute onset of impaired consciousness in the emergency department.
METHODS: This review is based on pertinent articles retrieved by a selective search of PubMed and on the AWMF guidelines on the most common causes of impairment of consciousness.
RESULTS: Impairments of consciousness are classified as quantitative (reduced wakefulness) or qualitative (abnormal content of consciousness). Of all such cases, 45-50% have a primary neurological cause, and approximately 20% are of metabolic or infectious origin. Some cases are due to intoxications, cardiovas - cular disorders, or psychiatric disorders. Important warning signs ("red flags") in acute onset of impaired consciousness are a hyperacute onset, pupillomotor disturbances, focal neurologic deficits, meningismus, headache, tachycardia and tachypnea (with or without fever), muscle contractions, and skin abnormalities. Patients with severely impaired consciousness should be initially treated in the shock room according to the ABCDE scheme.
CONCLUSION: Acute onset of impaired consciousness is a medical emergency. Red flags must be rapidly recognized and treatment initiated immediately. Patients with severely impaired consciousness of new onset and uncertain cause, status epilepticus, lack of protective reflexes, or a new, acute neuro - logic deficit should be admitted via the resuscitation room.
The matheral is used as a device for cleaning the teeth or asa cosmetic. It has improved rheological properties and stabilityand improved complex viscosity and Gi-valuies and no hightemperatures and long vacuum are required. The method iscontinuous and is realized by forming first low-viscosityhomogenous suspension of at least one nonaqueous solvent andthickener or a gelatinous agent at atmospheric conditions andtemperature ranging from 90 to 130°F (32-55°C). Then a secondlow-viscosity homogenous suspension is formed including water andat least one additive at atmospheric pressure and temperatureranging from 90 to 130°F (32-55°C). A low viscosity mixture isformed from the first and second low-voscosity mixture andtemperature range from 90 to 130°F (32-55°C) for 0.1 to 5 s. Thelow-viscosity mixture is converted to non-Newtonian at atmosphericpressure, temperature from 65 to 120°F (18-49°C) and in staticcondition. The non-Newtonian mixture produced is deaerated underconditions of vacuum at temperature ranging from 80 to 120°F(26-49°C) until the formation of non-Newtonian paste- orcream-like mateiral.16 claims, 1 figure.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II), also known as des-γ-carboxyprothrombin (DCP) or acarboxy prothrombin, is an abnormal form of prothrombin induced by vitamin K absence or antagonist-II. The study is intended to evaluate the diagnostic efficiency of Protein Induced by Vitamin K Absence or antagonist-II(PIVKA-II). PIVKA-II as an effective tumor marker for hepatocellular carcinoma(HCC) has been widely used in the western countries where most cases are hepatitis C virus(HCV) related.However, the majority of HCCs in China are HBV related. Despite the extensive application of PIVKA-II in some hospitals from China, the diagnostic efficiency including sensitivity,specificity,positive predictive value and negative predictive value still needs more clinical data to evaluate. The research purposes list as follows：1.Determination of diagnostic Cut-off value 2.Evaluation of diagnostic efficiency of PIVKA-II 3.Evaluation of the combination of PIVKA-II and other tumor markers for HCC. This study is an international multicenter study joined by several hospitals in China,Singapore,Thailand and Vietnam. Participants including healthy control,HCC,metastatic liver cancer,HBV and liver cirrhosis are consecutively recruited into the cohort. All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum samples were tested for PIVKA-II,Alpha-fetoprotein(AFP)，alpha-fetoprotein L3 and biochemical indexes including ALT,AST,GGT,AFU,etc. The diagnosis of HCC was based on histopathology. All HCC diagnoses were confirmed at the time of analysis.The Student's t-test (or Mann-Whitney test) was used to compare continuous variables, and the chi-square test (or Fisher's exact test) was used for categorical variables. A receiver operator characteristic (ROC) curve was used to assess the performance characteristic of PIVKA-II,AFP,AFP-L3 measurement.
Decision making and patient selection for isolated occlusion of the M2 segment of the middle cerebral artery is challenging, with the efficacy of treatment for such distal occlusions still controversial in recent studies, as occlusion in such small and thin vessels tends to manifest with less severe symptoms initially and hold higher surgical risks. It is even less clear which endovascular technique is more effective for this type of occlusion, with the choice usually left to the radiologist's preference. We conducted a controlled prospective study of consecutive patients presenting to Novara Hospital with an acute M2 occlusion diagnosed at the AngioCt and, following a predetermined randomization, we divided them into two treatment arms with either stent retriever aspiration (SRa) or direct aspiration (DA). All patients were examined on admission, at discharge and after 3 months, and clinical data as well as mRS and NIHSS scale scores were recorded. Our primary aim was to evaluate the difference in recanalization rate in the two groups by comparing the angiographic eTICI obtained with the two techniques. We then investigated whether there were differences in clinical outcomes and complications. Our data confirm a good recanalization rate with an eTICI ≥ 2b in 76.19% of patients in the cohort. An overall good outcome was achieved in 57% of patients as ∆NIHSS and in 50.79% of patients considering mRS. We found no statistically significant difference in recanalization rate nor higher complication rate in either the SRa or DA group. Both techniques are safe, effective and can be considered equally.
The extraction of ACTH and gonadotropins from the same batch of whole pituitary material e.g. hog pituitary material, comprises extracting the ACTH with acidified aqueous acetone, containing 50 to 85 per cent by volume acetone, at a pH below 4, and subjecting the separated insoluble residue to aqueous extraction at a pH from 7,1 to 10,0 to extract the gonadotropins.  The gonadotropins may be precipitated by addition of ethanol, or the extract may be adjusted to a pH between 3 and 7 and the gonadotropin-inert proteins precipitated by addition of a water-soluble zinc salt e.g. acetate, chloride or nitrate, to a concentration of 0,01 to 1,0 molar, prior to the precipitation of the gonadotropins as a zinc complex by the addition of an organic precipitating agent e.g. ethanol (10 to 50 per cent by volume), monohydroxyalkanes, or aliphatic ketones having less than 4 carbon atoms.  Extraction of the precipitated zinc complex with aqueous phosphate solution e.g. mono- or dibasic alkali metal phosphates, at pH 7 to 9, which may contain an organic precipitating agent (25 to 55 per cent by volume) results in a supernatent liquid, which contains the gonadotropins free from zinc and inert substances, from which the hormone is recovered by precipitation.  Alternatively, the zinc can be removed from the gonadotropin preparation by an ion exchange procedure or dialysis in the presence of a sequestering agent.  The hormone may be further purified by fractionation with ammonium sulphate at pH 4,5 to 8,0.  The process takes place at a temperature of less than 10 DEG C.
Ovarian cancer, an aggressive malignancy of the female reproductive tract, is frequently linked to an elevated risk of thrombotic events. This association is manifested by a pronounced rise in platelet counts and activation levels. Current research firmly supports the pivotal role of platelets in the oncogenic processes of ovarian cancer, influencing tumor cell proliferation and metastasis. Platelets influence these processes through direct interactions with tumor cells or by secreting cytokines and growth factors that enhance tumor growth, angiogenesis, and metastasis. This review aims to thoroughly dissect the interactions between platelets and ovarian cancer cells, emphasizing their combined role in tumor progression and associated thrombotic events. Additionally, it summarizes therapeutic strategies targeting platelet-cancer interface which show significant promise. Such approaches could not only be effective in managing the primary ovarian tumor but also play a pivotal role in preventing metastasis and attenuating thrombotic complications associated with ovarian cancer.
Phyto material tablets, tablet vaporizers, methods and apparatus for forming phyto material tablets. The tablets are formed to increase vaporization efficiency.  Tablets can include break regions to facilitate fracturing into multiple pieces for vaporization. The tablets can also include multiple layers of different phyto material mixtures.    Compression molds are used to shape the tablets. The compression molds can be provided on a rotational assembly to facilitate rapid manufacturing of multiple tablets.  The vaporizers include heating chambers that are configured to increase the surface area of the tablets exposed for vaporization. The heating chambers include compression or fracture members that compress and/or encourage fracturing of the tablets to assist vaporization.
20 men and women of healthy weight will participate in this study. The complete study design will be a 2 x 2 mixed factorial design, with the between-subject factor of order and a within-subject factor of eating condition (meal or grazing). Depending upon the eating condition, participants will be provided with a morning meal and an afternoon meal (meal) or two small meals and three snacks to be consumed every 2-3 hours (grazing). The types of foods and amount of foods provided to participants will be identical in each condition; the only difference in the conditions is the time spacing during the day when the foods are consumed. The primary dependent variable will be amount, both grams and energy, of food consumed during an ad libitum meal consumed in the evening at the completion of the meal condition, overall daily energy intake, and ratio of daily energy intake to energy expenditure. It is hypothesized that the grazing condition will produce lower consumption during an evening ad libitum meal, lower daily energy intake, and a lower ratio of energy intake to energy expenditure than the meal condition.
Multivitamins and multi-mineral supplements are widely used as a remedy for lack of proper nutrition. However, they tend to be scarcely assimilated, and more and more scientific reports claim that they are relatively useless if not harmful. This invention is an answer to this problem, as it provides a novel product, based on the nutritional bounty of cyanobacterial blue-green algae, and reinforced by foods and herbal extracts rich in one or more of the vitamins or minerals missing or scarce in the cyanobacterial blue-green algae. The result is a multivitamin and multi-mineral supplement that is completely organic and, being from alimentary and herbal sources that are recognized as foods by our organism, are much better assimilated. This invention provides an optimal solution to the conundrum we face today: the standard contemporary diet does not provide enough nutrition, with negative consequences on our health; but the inorganic and synthetic supplements we consume are not really foods, and so are ineffective. The product we have invented is an effective and innovative answer to this problem.
Neoral has increased bioavailability compared to Sandimmune. The absolute bioavailability of cyclosporine administered as Sandimmune is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. The absolute bioavailability of cyclosporine administered as Neoral has not been determined in adults. In studies of renal transplant, rheumatoid arthritis and psoriasis patients, the mean cyclosporine AUC was approximately 20% to 50% greater and the peak blood cyclosporine concentration (Cmax) was approximately 40% to 106% greater following administration of Neoral compared to following administration of Sandimmune. The dose normalized AUC in de novo liver transplant patients administered Neoral 28 days after transplantation was 50% greater and Cmax was 90% greater than in those patients administered Sandimmune. AUC and Cmax are also increased (Neoral relative to Sandimmune) in heart transplant patients, but data are very limited. Although the AUC and Cmax values are higher on Neoral relative to Sandimmune, the predose trough concentrations (dose-normalized) are similar for the two formulations.

Following oral administration of Neoral, the time to peak blood cyclosporine concentrations (Tmax) ranged from 1.5 to 2.0 hours. The administration of food with Neoral decreases the cyclosporine AUC and Cmax. A high fat meal (669 kcal, 45 grams fat) consumed within one-half hour before Neoral administration decreased the AUC by 13% and Cmax by 33%. The effects of a low-fat meal (667 kcal, 15 grams fat) were similar.

The effect of T-tube diversion of bile on the absorption of cyclosporine from Neoral was investigated in eleven de novo liver transplant patients. When the patients were administered Neoral with and without T-tube diversion of bile, very little difference in absorption was observed, as measured by the change in maximal cyclosporine blood concentrations from pre-dose values with the T-tube closed relative to when it was open: 6.9 ± 41% (range, 55% to 68%).
Nogapendekin alfa inbakicept-pmln is an interleukin-15 (IL-15) receptor agonist. It is a soluble complex consisting of (a) nogapendekin alfa (a human IL-15N72D variant, 114 amino acids) bound to (b) inbakicept [a dimeric human IL-15Rα sushi domain (65 amino acids)/human IgG1 Fc fusion protein (232 amino acids)]. Each fully assembled nogapendekin alfa inbakicept-pmln complex consists of a single inbakicept and two nogapendekin alfa components. Each IL-15N72D component is bound to one of the IL-15Rα sushi domains.

The recombinant protein complex is produced by a recombinant cell line that was created by transfecting a Chinese hamster ovary (CHO-K1) cell line with plasmids carrying genes for the IL-15N72D and IL-15RαSu/IgG1 Fc proteins. Purification of the product is achieved by conventional chromatography. The molecular weight of the deglycosylated nogapendekin alfa inbakicept-pmln complex is 92,106.5 Da. The molecular weights of the individual deglycosylated sub-units are 66565.6 Da (dimer) and 12,770.45 Da for the IL-15RαSu/IgG1 Fc domain and the IL-15N72D domain, respectively.

ANKTIVA (nogapendekin alfa inbakicept-pmln) solution is a clear to slightly opalescent, colorless to slightly yellow solution provided in a single-dose vial containing 400 mcg in 0.4 mL for intravesical administration upon dilution [see Dosage and Administration ( 2)] . Each vial also contains dibasic sodium phosphate (0.57 mg), monobasic potassium phosphate (0.54 mg), sodium chloride (3.27 mg) and Water for Injection, USP. Hydrochloric acid and sodium hydroxide is added to adjust the pH to 7.4.
The invention discloses a nux vomica alkaloid patch for treating local myalgia and arthralgia and a preparation method. The patch consists of a medicine storage magazine, a backing layer and an anti-sticking layer, wherein the medicine storage magazine comprises nux vomica total alkaloid with parts of strychnine removed, pressure-sensitive adhesive and transdermal absorption accelerant; the nux vomica has an obvious clinic curative effect on local myalgia and arthralgia caused by rheumatism and traumatic injury; the main active ingredient of the nux vomica is nux vomica total alkaloid, but the strychnine has the disadvantages of big toxin and high ratio in total alkaloid amount, and is likely to generate the toxic symptom when being orally taken; and a poisoning risk due to the damage of patient keratoderma may be caused even if the nux vomica is externally applied. Compared with the nux vomica total alkaloid patch nux vomica alkaloid patch, the external transdermal absorption rate of the strychnine in the patch disclosed by the invention is obviously lowered, and the concentration of the strychnine in the skin and the muscle on the belly pasting position of a mouse is obviously lowered. Compared with the traditional black plaster and adhesive plaster matrix in the traditional Chinese medicine, the patch disclosed by the invention is characterized by having the characteristic that a high-polymer pressure-sensitive adhesive with smaller skin irritation and irritability is selected, and the adhesion can be better. The patch disclosed by the invention has the advantages of high effective ingredient content, big transdermal absorption amount, and high medicine concentration of skin and muscle of the pasted position. The patch production equipment and the technology are mature, and the invention is suitable for large-scale industrial production.